newsfilter
← Latest News
Business Wire·

Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors

​Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointments of Edward Hu and Kate Hermans